As Sandoz and Just-Evotec Biologics announce a new partnership, Celltrion secures tender wins in Italy and Belgium, and Alvotech begins testing its golimumab biosimilar in patients with rheumatoid arthritis.
As Sandoz and Just-Evotec Biologics announce a new partnership, Celltrion secures tender wins in Italy and Belgium, and Alvotech begins testing its golimumab biosimilar in patients with rheumatoid arthritis.
Sandoz and Just-Evotec Biologics Partnership
Sandoz and Just-Evotec Biologics announced that they will join forces for a multiyear collaboration to develop and manufacture multiple biosimilar products. The partnership will grand Sandoz access to Just-Evotec Biologics’ proprietary drug substance development platform and manufacturing technology.
Sandoz will use Just-Evotec Biologics’ resources to expand its current biosimilar pipeline from 15 products to 24 products. Just-Evotec Biologics will receive a “double-digit-million figure upfront” followed by $640 million in future payments that would be dependent on successful developments progress. The company will also receive additional undisclosed payments based on commercial manufacturing progress.
“This strategic partnership is founded on a strong shared sense of purpose and commitment to use disruptive technology with lower operational costs to deliver high-quality biosimilars at scale to patients around the world. It provides us with additional capabilities to support the strategic expansion of our pipeline with new assets and to begin immediately transitioning our early biosimilar pipeline,” said Richard Saynor, CEO of Sandoz.
Celltrion Wins Tenders
Celltrion Healthcare said it won bids in Belgium and 3 provinces in Italy to supply its bevacizumab biosimilar (Vegzelma) for the treatment of metastatic colorectal and breast cancer, according to a report from Korea Biomedical Review.
The Italian tender will last for 2 to 3 years in Lombardy, Emilia Romagna, and Toscana. The Belgian tender will last for 2 years and apply to the Brugge Regional Hospital Group and the Onze Lieve Vrouw General Hospital.
“Since expanding direct sales to all products in Europe last year, we have been achieving significant results in the bidding market based on the local subsidiary's flexible pricing policy and synergies with the performance of our existing anti-cancer products,” said Yoo Won-sik, the general manager of Celltrion Healthcare Italy, in a statement.
Alvotech Begins Golimumab Clinical Trial
Alvotech shared that it initiated a confirmatory study for AVT05, a biosimilar that references Simponi and Simponi Aria (golimumab). The objective of the study is to compare the safety, efficacy, and immunogenicity profiles between the biosimilar and reference product in patients with moderate to severe rheumatoid arthritis.
The study is a randomized, double-blind, 2-arm, multicenter trial and will evaluate both products through 16 weeks. The news comes after Alvotech announced that it began a pharmacokinetic study for AVT05 in January 2023.
“It is a pleasure to be able to mark another clinical milestone in our biosimilars development pipeline…. This is part of our strong commitment to improve patient lives by expanding access to affordable biologics globally,” said Joseph McClellan, chief scientific officer at Alvotech, in a statement.
AON Saves Over $243 Million With High Biosimilar Adoption
April 22nd 2024Thanks to high biosimilar adoption rates within the community oncology setting, American Oncology Network (AON) saved upwards of $243 million between 2020 and 2023, according to a presentation at the Festival of Biologics USA conference in San Diego, California.
Decoding the Patent Puzzle: Navigating the Legal Landscape of Biosimilars
March 17th 2024On this episode of Not So Different, Ha Kung Wong, JD, an intellectual patent attorney and partner at Venable LLP, details the confusing landscape that is the US patent system and how it can be improved to help companies overcome barriers to biosimilar competition.
Julie Reed: Why 2024 Is Important for Biosimilars
April 17th 2024Julie Reed, executive director of the Biosimilars Forum, showcases how the biosimilar industry is expected to develop throughout 2024, including major policy changes and hope for continued improvement in market share for adalimumab biosimilars.
Biosimilars Rheumatology Roundup for February 2024—Podcast Edition
March 3rd 2024On this episode of Not So Different, The Center for Biosimilars® revisited all the major rheumatology biosimilar news from February 2024, including the FDA approval of the 10th adalimumab biosimilar, the promise for an oral delivery system for ustekinumab, and the impact of adalimumab products on COVID-19 antibodies.
Alvotech’s Stelara Biosimilar, Selarsdi, Receives FDA Approval
April 16th 2024Alvotech’s Selarsdi (ustekinumab-aekn), a biosimilar referencing Stelara (ustekinumab), gained FDA approval, making it the second ustekinumab biosimilar and second for the company to be given the green light for the American market.
Global Biosimilar Market Projected to Reach $1.3 Trillion by 2032
April 11th 2024The global biosimilar market is projected to surge from $25.1 billion in 2022 to approximately $1.3 trillion by 2032, with a compound annual growth rate of 17.6%, driven mainly by the increasing prevalence of cancer and the cost-effectiveness of biosimilars, as outlined in a report by Towards Healthcare.